Effectiveness and safety of GLP ‐1 receptor agonists in craniopharyngioma patients with obesity: A multicentre real‐world study
Open accessAbstract
Aims: Acquired hypothalamic obesity (aHO) following craniopharyngioma (CP) is a challenging condition with limited therapeutic options. This study aimed to assess the real‐world effectiveness and safety of GLP‐1 RAs in this population. Materials and Methods: CranioGLP1 is a retrospective multicentre study including 116 adults with aHO treated with one or more GLP‐1 RAs across 16 French obesity centres. Demographic, clinical, and therapeutic data were collected from medical records. Weight outcomes, adverse events, and predictors of response were analysed. Results: Patients had a mean age of 44.4 ± 13.5 years and a mean BMI of 40.1 ± 8.6 kg/m 2 , 42% had type 2 diabetes. Over a mean follow‐up of 44 months, mean weight loss was −4.6% (±12.5), with high interindividual variability; 51% achieved ≥5% weight loss, and 28% ≥10%. Semaglutide (mean dose 1.2 mg/week) was associated with the greatest reduction (−6.8%), particularly in patients without diabetes (−8.5% ± 12.3 vs. −3.9% ± 10.0 in those with diabetes; p = 0.032). Endocrine adverse events occurred in 12% and 10% of patients with adrenal or vasopressin deficiency decompensation, respectively, with 8% requiring hospitalisation. Gastrointestinal intolerance led to treatment discontinuation in 13% of cases. Conclusions: GLP‐1 RAs at submaximal doses induce moderate, yet clinically meaningful weight loss in adults with aHO, with semaglutide showing the highest efficacy. Given the non‐negligible risk of hormonal decompensation, specific endocrine monitoring is essential.
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
A multicenter retrospective study of more than 100 individuals treated with GLP1RAs demonstrated that weight loss is achievable.
“A multicenter, retrospective study of more than 100 individuals treated with GLP1RAs also demonstrated that weight loss is achievable, and highlights important safety considerations regarding using these medications in individuals with concomitant AVP-D and AI (43).”
From Approach to the patient with acquired hypothalamic syndrome (2026) · cites this paper as [43]
The multicenter retrospective study highlights important safety considerations regarding using GLP1RAs in individuals with concomitant AVP-D and AI.
“A multicenter, retrospective study of more than 100 individuals treated with GLP1RAs also demonstrated that weight loss is achievable, and highlights important safety considerations regarding using these medications in individuals with concomitant AVP-D and AI (43).”
From Approach to the patient with acquired hypothalamic syndrome (2026) · cites this paper as [43]
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Cites
Once-Weekly Semaglutide in Adults with Overweight or Obesity
Wilding, J. P. H., Batterham, R. L., Calanna, S., Davies, M., Van Gaal, L. F., Lingvay, I., McGowan, B. M., Rosenstock, J., Tran, M. T. D., Wadden, T. A., et al. (2021) · New England Journal of Medicine · doi:10.1056/nejmoa2032183 · Cited by 5,205 · see citing works
Davies, M., Færch, L., Jeppesen, O. K., Pakseresht, A., Pedersen, S. D., Perreault, L., Rosenstock, J., Shimomura, I., Viljoen, A., Wadden, T. A., et al. (2021) · The Lancet · doi:10.1016/s0140-6736(21)00213-0 · Cited by 1,419 · see citing works
Garber, A., Henry, R., Ratner, R., Garcia-Hernandez, P. A., Rodriguez-Pattzi, H., Olvera-Alvarez, I., Hale, P. M., Zdravkovic, M., & Bode, B. (2009) · The Lancet · doi:10.1016/s0140-6736(08)61246-5 · Cited by 1,057 · see citing works
The arcuate nucleus mediates GLP-1 receptor agonist liraglutide-dependent weight loss
Secher, A., Jelsing, J., Baquero, A. F., Hecksher-Sørensen, J., Cowley, M. A., Dalbøge, L. S., Hansen, G., Grove, K. L., Pyke, C., Raun, K., et al. (2014) · Journal of Clinical Investigation · doi:10.1172/jci75276 · Cited by 961 · see citing works
Sorli, C., Harashima, S.-I., Tsoukas, G. M., Unger, J., Karsbøl, J. D., Hansen, T., & Bain, S. C. (2017) · The Lancet Diabetes & Endocrinology · doi:10.1016/s2213-8587(17)30013-x · Cited by 745 · see citing works
Gorgojo-Martínez, J. J., Mezquita-Raya, P., Carretero-Gómez, J., Castro, A., Cebrián-Cuenca, A., de Torres-Sánchez, A., García-de-Lucas, M. D., Núñez, J., Obaya, J. C., Soler, M. J., et al. (2022) · Journal of Clinical Medicine · doi:10.3390/jcm12010145 · Cited by 358 · see citing works
Muller, H. L., Gebhardt, U., Teske, C., Faldum, A., Zwiener, I., Warmuth‐Metz, M., Pietsch, T., Pöhl, F., Sørensen, N. S., & Calaminus, G. (2011) · European Journal of Endocrinology · doi:10.1530/eje-11-0158 · Cited by 303 · see citing works
GLP-1 and weight loss: unraveling the diverse neural circuitry
Kanoski, S. E., Hayes, M. R., & Skibicka, K. P. (2016) · American Journal of Physiology-Regulatory, Integrative and Comparative Physiology · doi:10.1152/ajpregu.00520.2015 · Cited by 290 · see citing works
van Iersel, L., Brokke, K. E., Adan, R. A. H., Bulthuis, L. C. M., van den Akker, E. L. T., & van Santen, H. M. (2019) · Endocrine Reviews · doi:10.1210/er.2018-00017 · Cited by 146 · see citing works
GLP-1 analogues as a new treatment option for hypothalamic obesity in adults: report of nine cases
Zoicas, F., Droste, M., Mayr, B. M., Buchfelder, M., & Schöfl, C. (2013) · European Journal of Endocrinology · doi:10.1530/eje-12-0997 · Cited by 121 · see citing works
Weight Gain in Craniopharyngioma - A Model for Hypothalamic Obesity
Ahmet, A. H., Blasér, S., Stephens, D., Guger, S., Rutka, J. T., & Hamilton, J. T. (2006) · Journal of Pediatric Endocrinology and Metabolism · doi:10.1515/jpem.2006.19.2.121 · Cited by 104 · see citing works
Roth, C. L., Perez, F. A., Whitlock, K. B., Elfers, C., Yanovski, J. A., Shoemaker, A. H., & Abuzzahab, M. J. (2021) · Diabetes, Obesity and Metabolism · doi:10.1111/dom.14224 · Cited by 87 · see citing works
Roth, C. L., Scimia, C., Shoemaker, A. H., Gottschalk, M., Miller, J., Yuan, G., Malhotra, S., & Abuzzahab, M. J. (2024) · The Lancet Diabetes & Endocrinology · doi:10.1016/s2213-8587(24)00087-1 · Cited by 76 · see citing works
Lomenick, J. P., Buchowski, M. S., & Shoemaker, A. H. (2016) · Obesity · doi:10.1002/oby.21493 · Cited by 58 · see citing works
Management of Hypothalamic Obesity
Muller, H. L. (2020) · Endocrinology and Metabolism Clinics of North America · doi:10.1016/j.ecl.2020.05.009 · Cited by 44 · see citing works
Wang, K., Fleming, A. J., Johnston, D. L., Zelcer, S. M., Rassekh, S. R., Ladhani, S., Socha, A., Shinuda, J., Jaber, S., Burrow, S., et al. (2017) · Clinical Obesity · doi:10.1111/cob.12224 · Cited by 42 · see citing works
Effects of glucagon-like peptide-1 receptor agonists on fluid intake in healthy volunteers
Winzeler, B., da Conceição, I., Refardt, J., Sailer, C. O., Dutilh, G., & Christ-Crain, M. (2020) · Endocrine · doi:10.1007/s12020-020-02394-2 · Cited by 33 · see citing works
Simmons, J. H., Shoemaker, A. H., & Roth, C. L. (2012) · Hormone Research in Paediatrics · doi:10.1159/000339469 · Cited by 29 · see citing works
Perez, F. A., Elfers, C., Yanovski, J. A., Shoemaker, A. H., Abuzzahab, M. J., & Roth, C. L. (2021) · Diabetes, Obesity and Metabolism · doi:10.1111/dom.14366 · Cited by 29 · see citing works
Thondam, S. K., Cuthbertson, D. J., Aditya, B. S., MacFarlane, I. A., Wilding, J. P. H., & Daousi, C. (2012) · Clinical Endocrinology · doi:10.1111/j.1365-2265.2012.04368.x · Cited by 28 · see citing works
Gatta‐Cherifi, B., Mohammedi, K., Cariou, T., Poitou, C., Touraine, P. A., Raverot, G., Brue, T. C., Chanson, P., Illouz, F., Grunenwald, S., et al. (2024) · European Journal of Endocrinology · doi:10.1093/ejendo/lvae024 · Cited by 27 · see citing works
Self-citationvan Schaïk, J., Begijn, D. G. A., van Iersel, L., Vergeer, Y., Hoving, E. W., Peeters, B., & van Santen, H. M. (2020) · Obesity Facts · doi:10.1159/000509302 · Cited by 25 · see citing works
Treatment of Hypothalamic Obesity With GLP-1 Analogs
Dimitri, P., & Roth, C. L. (2024) · Journal of the Endocrine Society · doi:10.1210/jendso/bvae200 · Cited by 25 · see citing works
Semaglutide treatment of hypothalamic obesity – a real-life data study
Svendstrup, M., Rasmussen, A. K., Kistorp, C., Klose, M., & Andreassen, M. (2024) · Pituitary · doi:10.1007/s11102-024-01429-5 · Cited by 23 · see citing works
Bretault, M., Carette, C., Zaharia, R., Vychnevskaia, K., Bouillot, J.-L., Czernichow, S., & Raffin-Sanson, M.-L. (2020) · Diabetes & Metabolism · doi:10.1016/j.diabet.2019.07.004 · Cited by 20 · see citing works
Gjersdal, E., Larsen, L. B., Ettrup, K. S., Vestergaard, P., Nielsen, E. H., Karmisholt, J., Muller, H. L., & Dal, J. (2024) · Pituitary · doi:10.1007/s11102-024-01426-8 · Cited by 20 · see citing works
Semaglutide for Treating Obesity Induced by Craniopharyngioma Resection: A Successful Case Study
Sciacovelli, C., Moschione, G., Garelli, S., & Pagotto, U. (2023) · JCEM Case Reports · doi:10.1210/jcemcr/luad074 · Cited by 19 · see citing works
Castro-Dufourny, I., Carrasco, R., & Pascual, J. M. (2017) · Endocrinología Diabetes y Nutrición · doi:10.1016/j.endinu.2016.10.006 · Cited by 17 · see citing works
Elfers, C., Simmons, J. H., & Roth, C. L. (2012) · Hormone Research in Paediatrics · doi:10.1159/000338464 · Cited by 15 · see citing works
Faucher, P., Carette, C., Jannot, A., Gatta‐Cherifi, B., Straaten, A. V., Piquet, M., Raverot, G., Alligier, M., Batisse, T., Ziegler, O., et al. (2022) · Obesity Surgery · doi:10.1007/s11695-022-06079-9 · Cited by 14 · see citing works
Self-citationNakhleh, A., Shehadeh, N., & Mansour, B. (2024) · Pituitary · doi:10.1007/s11102-024-01451-7 · Cited by 13 · see citing works
Czernichow, S., Rassy, N., Carette, C., Shoung, N., Hu, F. B., & Rives‐Lange, C. (2025) · Obesity Reviews · doi:10.1111/obr.13890 · Cited by 10 · see citing works
Darmon, P., Bauduceau, B., Bordier, L., Detournay, B., Gautier, J., Gourdy, P., Jornayvaz, F. R., Lecornet‐Sokol, E., Penfornis, A., Prévost, G., et al. (2023) · Médecine des Maladies Métaboliques · doi:10.1016/j.mmm.2023.10.007 · Cited by 10 · see citing works
He, M., Xu, H., Ying, Z., Chen, Y., & Li, X. (2024) · Endocrine Connections · doi:10.1530/ec-24-0493 · Cited by 7 · see citing works
Hulsmann, S. C., Hoving, E. W., Bakker, B., Janssens, G. O. R. J., van Schaïk, J., de Vos‐Kerkhof, E., Tissing, W. J. E., & van Santen, H. M. (2025) · Endocrine Connections · doi:10.1530/ec-24-0533 · Cited by 3 · see citing works
Flagged first, then by citations
Cited by
Sorted by citations
Gunasekaran, P., Inban, P., Agrawal, A., Thai, A., Aravazhi, P. S., Tariq, H., Prajjwal, P., & John, J. (2026) · Disease-a-Month · doi:10.1016/j.disamonth.2026.102113 · Cited by 2 · see citing works
Tirzepatide-associated hyponatremia in a patient with known arginine vasopressin deficiency
Caputo, C. (2026) · JCEM Case Reports · doi:10.1210/jcemcr/luag110 · Cited by 1 · see citing works
Quality of life, morbidity, mortality, and long-term prognosis after craniopharyngioma
Muller, H. L. (2026) · Frontiers in Endocrinology · doi:10.3389/fendo.2026.1768254 · Cited by 1 · see citing works
Approach to the patient with acquired hypothalamic syndrome
Grishman, E. K., & McCormack, S. E. (2026) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/clinem/dgag197
Obesity medications and acquired hypothalamic obesity in adults: A two-case experience
Lang, H., Dorand, M. F., Hassan, M., & Richards, J. R. (2026) · Obesity Pillars · doi:10.1016/j.obpill.2026.100246
Vega‐Beyhart, A., Sevilla, M., Bassoumi, D., Borchin, R. L., Arroyo-Ripoll, O. F., Martínez, W. A. R., Berrocal, V. R., & Araujo-Castro, M. (2026) · Pituitary · doi:10.1007/s11102-026-01642-4
Разработка лекарственного вещества для ЛЕЧЕНИЯ САХАРНОГО ДИАБЕТА
Яременко, А. Н., Сысолятин, С. В., & Lenskii, M. A. (2025) · Южно-Сибирский научный вестник · doi:10.25699/sssb.2025.64.6.063
Lassen, P. B., Jacobi, D., Brindisi, M., Bonnet, J., Subtil, F., Bin, S., Abad, F., Poitou, C., Segrestin, B., Ledoux, S., et al. (2026) · Diabetes Obesity and Metabolism · doi:10.1111/dom.70697
Self-citationYokota, K., Nakagawa, T., Nakamura, Y., Okada, N., Kusuda, S., & Sone, M. (2026) · JCEM Case Reports · doi:10.1210/jcemcr/luag107
Cotta, O. R., Morgante, C., Giandalia, A., Angileri, F. F., Ferraù, F., & Cannavò, S. (2026) · Journal of Endocrinological Investigation · doi:10.1007/s40618-026-02950-z
Muller, H. L. (2026) · Frontiers in Endocrinology · doi:10.3389/fendo.2026.1895026
Semaglutide for Treating Paediatric Craniopharyngioma‐Related Obesity: A Multicentre Case Series
Dornberger, J., Barat, P., Aouchiche, K., Perge, K., Villanueva, C., Castets, S., Bouhours‐Nouet, N., Donzeau, A., Levaillant, L., Teinturier, C., et al. (2026) · Diabetes Obesity and Metabolism · doi:10.1111/dom.71403
- Authors
- Lambert, F., Guillon, E., Gatta‐Cherifi, B., CranioGLP1_FORCE Group, Soula, H., Poitou, C., & Faucher, P.
- Affiliations
- Assistance Publique – Hôpitaux de Paris (FR)
- Inserm (FR)
- Centre Hospitalier Universitaire de Bordeaux (FR)
- Nutrition and Obesities, Systemic Approaches—NutriOmique Research Group Sorbonne Université, Inserm Paris France
- Corresponding author
- Faucher, Pauline
- Venue
- Diabetes, Obesity and Metabolism
- Publisher
- Wiley
- Published
- 2025-10-28
- Volume
- 28
- Issue
- 1
- Pages
- 443-451
- ISSN
- 1462-8902 (ISSN-L)
- 1463-1326
- PMC
- PMC12673446
- OpenAlex
- W4415647748
- Cited by
- 12
- References
- 20
- Citations by year
- 2026: 11 · 2025: 1
- FWCI
- 8.18
- Type
- journal article
- Language
- en
- Open access
- hybrid
- doi.org
- Licence
- Locations
- Diabetes Obesity and Metabolism (publishedVersion, cc-by-nc-nd)
- PubMed (publishedVersion)
- HAL (submittedVersion)
- Funders
- Direction Générale de l’offre de Soins
- Assistance publique-Hôpitaux de Paris
- Topics
- Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Pituitary Gland Disorders and Treatments
- Health Sciences › Medicine › Pharmacology › Pharmacology and Obesity Treatment
- Life Sciences › Neuroscience › Endocrine and Autonomic Systems › Regulation of Appetite and Obesity
- Keywords
- GLP-1 receptor agonists, craniopharyngioma, semaglutide, weight loss, type 2 diabetes, adrenal insufficiency, vasopressin deficiency, endocrine adverse events, gastrointestinal intolerance, treatment safety, predictors of treatment response
- MeSH terms
- Glucagon-Like Peptide-1 Receptor Agonists, Semaglutide, Adult, Craniopharyngioma, Diabetes Mellitus, Type 2, Glucagon-Like Peptides, Female, France, Humans, Hypoglycemic Agents, Male, Middle Aged, Obesity, Pituitary Neoplasms, Retrospective Studies, Weight Loss, Treatment Outcome, Glucagon-Like Peptide 1
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
